

Title:

A systematic review of experimental strategies aimed at improving motor function after acute and chronic spinal cord injury.

Running title:

Systematic review of different strategies for improving motor function after SCI.

Authors:

Joyce Gomes-Osman^a, Mar Cortes^b, James Guest^c and Alvaro Pascual-Leone^a

Institutional Affiliations:

^a Berenson-Allen Center for Non-Invasive Brain Stimulation, Department of Neurology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA

^b Non-invasive Brain Stimulation and Human Motor Control Laboratory, Burke Medical Research Institute, Weill Cornell Medical College, White Plains, New York, USA

^c Department of Neurological Surgery, The Miami Project to Cure Paralysis, Lois Pope LIFE Centre, Miller School of Medicine, Miami, Florida, USA

Correspondence:

Alvaro Pascual-Leone, MD, PhD

Berenson-Allen Center for Noninvasive Brain Stimulation

Department of Neurology, Beth Israel Deaconess Medical Center

330 Brookline Ave

Boston, MA 02215

Email: apleone@bidmc.harvard.edu

Tel: 617-667-0203 Fax: 617-975-5322

Full mailing information:

Joyce Gomes-Osman, Berenson-Allen Center for Noninvasive Brain Stimulation, Department of Neurology, Beth Israel Deaconess Medical Center, 330 Brookline Ave Boston, MA, 02215, USA. Email: jgomes2@bidmc.harvard.edu; Tel: +1617-667-0203, Fax: +1617-975-5322.

Mar Cortes, Non-invasive Brain Stimulation and Human Motor Control Laboratory, Burke Medical Research Institute, Weill Cornell Medical College, 785 Mamaroneck Avenue, White Plains, NY, 10605, USA. Email: mcortes@burke.org; Tel: +1 914 368 3181.

James Guest, Department of Neurological Surgery, The Miami Project to Cure Paralysis, Lois Pope LIFE Centre, Miller School of Medicine, 1095 NW 14th Terrace, Miami, FL 33136, USA. Email: jguest@med.miami.edu, Tel: +1 305 243 8185.

Alvaro Pascual-Leone, Berenson-Allen Center for Noninvasive Brain Stimulation, Department of Neurology, Beth Israel Deaconess Medical Center, 330 Brookline Ave Boston, MA, 02215, USA. Email: apleone@bidmc.harvard.edu; Tel: +1617-667-0203, Fax: +1617-975-5322.

Abstract:

While various approaches have been proposed in clinical trials aimed at improving motor function after spinal cord injury in humans, there is still limited information regarding the scope, methodological quality and evidence associated with single-intervention and multi-intervention approaches. A systematic review carried out using the PubMed search engine and the keywords “spinal cord injury motor recovery” identified 1,973 records, of which 39 were selected (18 from the search records and 21 from reference list inspection). Study phase (clinicaltrials.org criteria) and methodological quality (Cochrane criteria) were assessed. Studies included proposed a broad range of single-intervention (encompassing cell therapies, pharmacology, electrical stimulation, rehabilitation) (encompassing cell therapies, pharmacology, electrical stimulation, rehabilitation), and multi-intervention approaches (that combined more than one strategy). The highest evidence level was for phase III studies supporting the role of multi-intervention approaches that contained a rehabilitation component. Quality appraisal revealed that the percentage of selected studies classified with high risk of bias by Cochrane criteria was as follows: random sequence generation=64%; allocation concealment=77%; blinding of participants and personnel=69%; blinding of outcome assessment=64%; attrition=44%; selective reporting=44%. The current literature contains a high proportion of studies with a limited ability to measure efficacy in a valid manner due to low methodological strength in all items of the Cochrane risk of bias assessment. Recommendations to decrease bias are discussed, and include increased methodological rigor in the study design and recruitment of study participants, and the use of electrophysiologic and imaging measures that can assess functional integrity of the spinal cord (and may be sufficiently sensitive to detect changes that occur in response to therapeutic interventions).

Keywords: spinal cord injury (SCI); human studies; cell transplantation; rehabilitation; electrophysiology.

Introduction

It is estimated that 30 individuals sustain an injury to the spinal cord every day in the United States.¹

There are approximately 2 million people living with the consequences of SCI worldwide, a relatively low number thought to reflect the higher mortality associated with acute SCI in developing countries.²

Injury to the spinal cord greatly disrupts information between the supraspinal centers and muscles, leading to varying degrees of paralysis that greatly impact one's functional ability and quality of life.

Despite the great advances in clinical management (including surgical decompression of the spinal cord, pharmacology and rehabilitation) and investigational efforts, recovery of motor function is still considered limited. The International Standards for Neurological Classification System for Spinal Cord Injury (ISNCSCI) developed by the American Spinal Injury Association (ASIA)^{3,4} is the most widely system for the classification of residual neurologic function after SCI. According to the ISNCSCI, approximately 55% of cases are incomplete (i.e., presence of varying degrees of sensory or motor activity below the neurological level of injury) and in the remaining 45% of cases, there is no sensory and/or motor function in the S4-5 sacral segments (classified as motor-complete) as determined by the motor and sensory testing.

Traditionally in SCI research, potential therapeutic approaches targeting motor-incomplete lesions focus on harnessing the neural plasticity of the spared axonal fibers for the activation of muscles below the injury level. While neurological improvements do occur, recovery of function it is still variable, and difficult to predict. However, the greatest challenge for the recovery of motor function is axonal regeneration across the injury site and the formation of new functional synapses, the overarching goal of approaches targeting motor-complete SCI. While there is evidence of partial tissue sparing even after complete SCI,⁵ the adult human injured spinal cord constitutes an inhospitable environment for

regeneration due to many factors, including the limited axonal growth response that is due to the presence of many molecules in the myelin debris and glial scar tissue that cause growth cone collapse.⁶

In addition to the challenges imposed by the lesion itself, the success of potential therapeutic approaches has been linked to the adoption of better practices in scientific design, methodology of research studies, and the development of sensitive outcome measures of spinal cord integrity and residual connectivity.²

These have to complement improved clinical assessments to better characterize the effects of the injury on the nervous system and changes that occur in response to therapeutic interventions.^{2,7} In addition, the use of combinatorial approaches^{8,9} may be more effective than single-intervention approaches by simultaneously targeting different injury mechanisms. There is recent promising evidence demonstrating recovery of stepping in rats with a transected spinal cord after a combinatorial approach incorporating locomotor training with electrical neuromodulation and a pharmacology agent.¹⁰ However, there have not been many practical efforts in this direction in humans.

The aims of this review were to: 1) perform an appraisal of the methodology of studies targeted at improving motor function in individuals with acute and chronic SCI; 2) identify the scope and evidence level associated with single-intervention (encompassing cell therapies, pharmacology, electrical stimulation, rehabilitation) and multi-intervention approaches (that combined more than one strategy) published in the literature to date; 3) identify the number of studies that incorporated an evaluation of spinal cord integrity and residual connectivity; 4) describe potential sources of bias in the selected studies; and, 5) make recommendations for future clinical trials in SCI.

Materials and Methods

On 2014-10-01, a PubMed search utilizing the following keywords "spinal cord injury motor recovery" was performed to identify studies aimed at improving motor function after SCI. In addition, on 2015-01-26, a second search was carried out using the following key words "spinal cord injury motor recovery" AND each of the following: "cell therapies", "electric stimulation", "pharmacology" and "rehabilitation".

between-group differences in AIS scores, Functional Independence Measure (FIM) Scores and Spinal Cord Independence Measure (SCIM) between those treated with minocycline and placebo for up to one year post-intervention.³⁵ Following evidence suggesting that dopamine can improve motor task acquisition, Maric et al³⁶ carried out a cross-over study to compare the effects of L-dopa and placebo. Twelve participants received L-Dopa (200 mg L-Dopa, 5 days per week for 6 weeks) or placebo prior to physical therapy (45 minutes, twice daily for 6 weeks) and there were no differences between the outcomes between the two groups after 12 weeks (AIS scores, FIM, WISCI-II [walking index for SCI]).³⁶

Kumru et al²⁵ performed a phase III study to assess the influence of non-invasive brain stimulation delivered in the form of high-frequency repetitive transcranial magnetic stimulation (rTMS), aimed at facilitating corticospinal excitability. Seventeen participants who had had a SCI between 3 and 12 months prior to study enrollment received rTMS or sham-rTMS (15 sessions, 5 days per week for 3 weeks) and engaged in a rehabilitation protocol for 5 hours per day, 5 days per week for 5 weeks.²⁵ There were no between-group differences, but pre-post changes reached significance for gait speed and lower extremity motor scores (LEMS) for the rTMS group.²⁵

Two phase-III studies have proposed locomotor training in acute SCI. Alcobendas-Maestro et al³⁷ compared the outcomes of 40 sessions of locomotor training delivered with a robotic orthosis (30 minutes per session) to overground walking training (one hour per session) in 75 participants with an SCI of less than 6 months. They found greater improvements in outcomes of walking function in the robotic orthosis group (FIM, WISCI, walking distance and LEMS), but no between-group difference in walking speed was found.³⁷ Dobkin et al³⁸ enrolled 175 participants with a SCI of at least 8 weeks in a study to compare the effects of a combined approach of locomotor training (either consisting of body weight supported treadmill training or conventional overground mobility training) and physical therapy, occupational therapy and nursing care delivered in 45 1-hour sessions. To minimize bias from differences in spontaneous recovery rates, the analysis was performed separately according to AIS classification at entry.³⁸ There was no between-group difference in walking speed, the primary outcome.³⁸

Two phase III studies assessed Chinese Medicine approaches. Wong et al³⁹ enrolled individuals who were injured at approximately 2 months and compared the outcomes of a group that received standard rehabilitation program in isolation with a group that additionally received electro-acupuncture targeting the Governic meridian. At the end of one year, the authors found significant pre-post changes in AIS scores in both groups, but only the acupuncture group exhibited significant pre-post changes in the FIM.³⁹ Li et al⁴⁰ performed a phase III study to assess the influence of Di Huang Yin Zi (DHYZ), a pharmacological approach with unclear mechanisms, in 60 individuals with acute SCI (approximately 4 weeks post-injury). Participants received either DHYZ or placebo (18 grams, twice daily) for 12 weeks, and authors reported greater increases in AIS motor scores in the DHYZ group when compared with placebo.⁴⁰

Approaches in chronic SCI

Table 4 lists all included studies in chronic SCI. There were a total of 6 phase I studies. Lima et al¹⁸ proposed the transplantation of olfactory mucosal autografts into the chronically injured spinal cord. A second independent study proposed the use of olfactory entheating cells.¹⁹ Yazdani et al²³ proposed a combinatorial approach that consisted of cell transplantation of bone-marrow mesenchymal stromal cells and Schwann cells, combined with rehabilitation. The remaining phase I chronic studies included a rehabilitation study that assessed automated locomotor training using a position-controlled gait-driven orthosis,⁴¹ an impedance-controlled robotic orthosis,⁴² and a study that assessed the effects of body-weight supported treadmill training combined with electrical stimulation.⁴³

Segal et al⁴⁴ carried out a phase II study to assess the effects of 4-aminopyridine, a potassium-channel blocker that has been associated with improved axonal conduction, particularly in demyelinated nerve fibers. Participants (various AIS grades) were randomized to a 3 month regimen of 4-aminopyridine, either delivered in the form of a low dose (6mg/day) or a high dose (30mg/day).⁴⁴ Comparisons were

made with an unblinded group that received a high dose (30mg/day). The authors reported significant pre-post increased AIS motor scores, only when all groups were collapsed together.⁴⁴

One phase II study has assessed the effect of locomotor training in 225 individuals who had sustained a chronic incomplete SCI and also examined the effects of a combinatorial approach consisting of manual facilitated body weight-supported step training on a treadmill and community reintegration.⁴⁵ The dose was variable, based on the participant's ambulatory capacity (5 times/week for non-ambulatory participants, 4 times/week for participants who required pronounced assistance and 5 times/week for ambulatory participants). After having completed a mean of 60.3 ± 53.24 sessions, the authors found significant pre-post improvements in the following outcome measures: LEMS, upper extremity motor scores (UEMS), 6-minute walk (speed and distance), and 10-meter walk (speed). In addition, using pre-established functional walking stratifications,⁴⁶ 33% of non-ambulatory participants became walkers, 47% of slow walkers improved to faster walkers, and overall AIS conversion rates from C to D was 28% (for AIS classification, see Table 1).⁴⁵

Four studies assessed the effects of combinatorial approaches for upper extremity function improvement. One phase II study assessed the effects of a single-session of transcranial magnetic stimulation paired with electrical stimulation on fine motor hand performance in 10 individuals with chronic SCI and found significant improvements on the Nine-Hole Peg Test measured at 20 minutes and 30 minutes post-stimulation.²⁶ A phase III study assessed the effects of task specific training (2 hours/day, 5 days a week for 3 weeks) delivered in isolation or combined with electrical stimulation of the median nerve in 24 participants, and found greater improvements in hand motor performance in the combined approach.²⁷ In a latter study with the same sample size, the authors found that the combination of task-specific training and electrical stimulation was associated with significantly larger improvements in hand motor performance than either intervention used in isolation.²⁸

The combination of task-specific training and electrical stimulation was further investigated by Hoffman et al.²⁹ In this phase III study, investigators compared the effects of functional electrical stimulation to submotor threshold electrical stimulation, each combined with either unimanual or bimanual task-specific training, utilizing the same dose and sample size (n=24) as in the prior studies.²⁹ While underpowered to detect changes between the approaches, the authors found that the unimanual group made greater changes in unimanual function, and the bimanual group made greater changes in bimanual function when compared with the control group, irrespective of stimulation type when compared to a waitlist control group.²⁹ Sadowski et al⁴⁷ assessed the effects of functional electrical stimulation during cycling in individuals with chronic SCI (n=25), and made comparisons with a control group (n=20) of individuals who were matched for age, gender, and duration, location and severity of injury. The authors found that those who participated in an FES cycling protocol made significantly greater improvements in AIS total scores, motor scores and FIM.⁴⁷

Three phase III studies proposed rehabilitation combinatorial strategies that included locomotor training. Field-Fote et al⁴⁸ compared the effects of manually-assisted treadmill training, treadmill training assisted with electrical stimulation, overground training assisted with electrical stimulation and passive locomotor training using a robotic orthosis (all delivered for 1-hour a day, 5 days a week for 12 weeks) in 27 individuals. The authors found significant pre-post improvements in walking speed and distance (measured by the 2-minute walk and 6-minute walk) when all groups were collapsed.⁴⁸ In a follow-up study⁴⁹ of the same approaches with a larger sample size that was adequately powered to detect statistical differences between the interventions (n=75), the authors found significant between-group differences for walking distance, with greatest effects observed with the overground training combined with electrical stimulation. Jones et al⁵⁰ conducted a study to assess the effects of activity-based therapy (ABT), which consists in an individualized rehabilitation program focused on muscle strengthening (including resistance and endurance) and locomotor training. Utilizing a randomized delayed intervention design, 48 individuals (AIS C and D) participated in ABT (up to 3-3hr sessions/week over 24 weeks). The average

documented treatment time was 89 ± 22.1 hours.⁵⁰ At post-test, there were significantly greater improvements in the ABT condition on AIS motor scores, LEMS, walking speed (10 meter walk) walking distance (6-minute walk), and on the Spinal Cord Injury Functional Ambulation Index.⁵⁰

Five studies assessed the effects of cell therapies, in isolation or combined with rehabilitation interventions, and found mixed results. Dai et al¹⁴ compared the delivery of mesenchymal stem cells using open surgery or delivered (dose: 4×10^7) using computed tomography to an inactive control in 27 individuals with chronic SCI with varying characteristics of injury severity. At a follow-up performed 6 months after, the authors reported significant pre-post improvements in AIS scores in the open surgery and computed tomography-guided transplant group, and significant improvements in AIS motor scores only in the computed tomography-guided transplant group.¹⁴ McKay-Sim et al²¹ assessed the effects of transplantation of culture-expanded autologous olfactory ensheathing cells (12-28 million) in 12 participants with thoracic complete injuries (6 individuals received the transplants and 6 matched control patients with thoracic level injury 1-3 years prior to enrollment), and found no functional improvements in any of the outcome measures, which were assessed up to 3 years post-intervention. The authors attributed these results to the lack of a rehabilitation protocol.²¹

Lima et al²⁰ assessed the influence of olfactory mucosal autografts and locomotor training in 20 participants with complete SCI. All participants engaged in rehabilitation (mean= 31.8 ± 6.8 h/week for 34.7 ± 30 weeks) prior to and following (32.7 ± 5.2 h/week for 92 ± 37.6 weeks) the olfactory mucosal autograft transplant.²⁰ The authors found pre-post improvements in LEMS and walking function (FIM and WISCI).²⁰ In addition, 15/20 participants (all whom had sustained motor-complete injuries) demonstrated electromyography activation below the level of injury, leading the authors to conclude that there was late neurological recovery.²⁰

Larson et al⁵¹ carried out a phase III study to compare outcomes of participation in an intense rehabilitation program between individuals with and without a history of a previous olfactory mucosal

autograft transplant. Utilizing an open-label design, they recruited individuals who had a prior olfactory mucosal cell transplant (privately performed), a matched control group (controlled for age, injury severity, gender and AIS classification) and a second non-matched control group. All 23 participants engaged in an intense exercise protocol for an average of 7.1 hours/week for approximately 4.6 months (137.3 total hours).⁵¹ With all groups collapsed, there were significant improvements in AIS scores at 60 days post-intervention, and no differences were found between those who received olfactory mucosal cell transplant and those who did not.⁵¹ The authors concluded that the intense rehabilitation approach was likely a key factor responsible for the functional improvements.⁵¹

Kishk et al²² assessed the effects of transplantation of flask-adherent bone marrow stromal cells and rehabilitation in individuals who had a SCI at least 6 months prior to study enrollment. Forty-four participants with variable injury levels and severity received mononuclear cells (dose: 5×10^6 to 10×10^6 /kg, administered intrathecally every month for 6 months), and 20 participants who did not agree to study procedures comprised the control group.²² All individuals participated engaged in rehabilitation 2-3 times/week.²² The authors found that the intervention group made significantly greater gains in AIS scores, but the amount of improvement was correlated with having an incomplete injury. Since the groups were not balanced for injury severity, this finding was of limited clinical value.²²

One study assessed the combination of daily intermittent hypoxia (Daih) and rehabilitation on locomotor outcomes in SCI.⁵² Using a double-blind, randomized crossover study, Daih (15-90 second intervals, fraction of inspired oxygen=0.9 for 5 days) or Daih-Sham were delivered in isolation or combined with subsequent walking training, in 19 individuals with incomplete SCI.⁵² The authors found that Daih increased walking speed (measured by the 6-minute walk) one day and two weeks post-administration. Furthermore, the combination of Daih and walking training was associated with greater improvements in walking endurance (measured by the 10-meter walk) than walking training alone and Daih alone at 5 days and one week post-administration.⁵²

Discussion

A systematic assessment of the literature reveals that various strategies have been proposed to improve motor function after spinal cord injury (including Cell therapy, Pharmacology, Rehabilitation, Electrical Stimulation/Neuroelectric device (delivered individually, or in combinatorial approaches containing each of these strategies). The highest evidence level available (level III) supports combinatorial approaches that contained a rehabilitation component. Quality appraisal of the included literature highlights that there are still few well-designed studies producing high-level evidence that can appropriately answer questions regarding the effectiveness of many approaches proposed. Among the sources of bias encountered, the most concerning were: the inclusion of highly heterogeneous samples; the lack of randomization and concealed allocation procedures; the absence of blinding procedures; and the use of outcomes with limited sensitivity. In addition, only few studies included measures of integrity and residual connectivity of spinal pathways.

The finding that combinatorial approaches comprised 43% of phase III studies in acute SCI and 77% of studies in chronic SCI is encouraging. Wenger et al¹⁰ demonstrated meaningful functional recovery of stepping in rats after a transection to the spinal cord following 4 weeks of body-weight supported treadmill training delivered in combination with electrical neurostimulation and serotonin agonists administered systemically. Our study of the human literature supports this experimental evidence¹⁰ by demonstrating that the strongest evidence for improved outcomes of motor function comes from trials that employed combinatorial approaches containing a rehabilitation component.^{25,27-29,38,39,48,49} Taken together, we believe that future clinical trials have greater potential for motor recovery if novel therapeutic strategies (such as neurostimulation and pharmacotherapy) are tested as adjuvant to rehabilitation.

The paucity of high-level evidence of studies from other modalities (including cell therapies, pharmacology, electrical stimulation/neuroelectric devices) should not be interpreted as a lack of effectiveness. Instead, this is partially an encouraging finding that reflects the high productivity in SCI

research in the last 17 years, characterized by increases in the number of phase-I and phase II studies suggesting promising novel treatment strategies. While the main objective of phase I and II trials is the assessment of safety and feasibility of a given intervention, many methodological concerns with the early stage trials were identified, and future trials need to be more carefully designed, in order to allow for inferences regarding preliminary efficacy that are useful in planning phase III studies.

The inclusion of participants with broad age range and diverse clinical characteristics (time since injury, injury severity) introduces insurmountable heterogeneity that is concerning when inferences regarding recovery are drawn based on group data. Spontaneous recovery rates have been shown to differ considerably based on the level and severity of the injury. There is evidence to support that as many as 10% of individuals with complete (AIS A injuries) will convert to AIS C and D (incomplete injuries) within the first year in the absence of any therapeutic intervention.² For those initially classified as AIS B, 15-40% will convert to AIS C, and approximately 40% of the remaining will convert to AIS D.² Eighty percent of individuals initially classified as AIS C will convert to AIS D within the first year.² In our opinion it is critical that future studies restrict the inclusion criteria to create homogeneous groups especially in studies enrolling individuals with acute and subacute injuries.⁵³ In studies with larger sample sizes, another option is to perform statistical analyses based on AIS level at entry.³⁸

Furthermore, nearly all studies used the ISNCSCI criteria as the primary outcome measure for neurologic recovery. While the AIS exam is the most widely used neurologic classification for SCI, it has a considerable degree of subjectivity, and requires formal training for the investigators/clinical staff in order to achieve optimal rates in terms of intra-rater and test-retest reliability⁵⁴ (although rarely reported in the studies assessed). We found that 69% of the studies included did not adopt blinding of participants, and 64% of studies did not adopt blinding procedures for the investigators. This is an important concern, because when recovery occurs, we often do not know why it happens due to the lack of mechanistic discriminative power of our clinical assessments. It is thus important to develop measures that allow change in particular pathways to be detected. Spinal cord integrity and residual connectivity was only

assessed in a few number of studies (28% and 26%, respectively). Given its importance in motor function, the development of sensitive outcome measures of viability of corticospinal pathways is an important direction given the limited sensitivity of currently available outcome measures to quantify neurologic impairments and changes that may occur in response to novel therapies.

We believe that such neurophysiologic and neuroimaging measures should be used to characterize spinal cord structure and physiology of the injury in future clinical trials. Potential approaches for assessing corticospinal conduction may involve the use of noninvasive or minimally invasive brain stimulation, electrophysiology and imaging techniques.⁷ For example, the quantification of motor evoked potentials elicited with TMS enables the assessment of functional integrity of the corticospinal tract, spinal nerve roots and motor pathway's projections to the muscles.⁵⁵ Moreover, more advanced TMS protocols, particularly the triple-pulse protocol that combines central and peripheral stimuli, enable accurate quantification of the number of corticospinal fibers with preserved conduction across a putative spinal injury level.⁵⁶ Finally, such neurophysiologic studies can be combined with diffusion tensor imaging and other advanced imaging methods,⁵⁷ to provide anatomical characterization of the structural integrity of the corticospinal tract, including alterations in fractional anisotropy (that assesses the axonal count and myelin content), axial diffusivity and radial diffusivity (that assesses the integrity of axons and myelin).⁷

Our search strategy captured only 18 of the 39 included articles. This can be explained by the difficulty in designing a search that identifies all of the different interventions of interest without requiring the need to review many thousands of abstracts. Although we employed multiple queries and inspected reference lists, it is possible that the search strategy employed herein may have been insufficient to detect all published studies for each approach (cell therapies, pharmacology, electrical stimulation, rehabilitation). Another limitation is that we did not include studies that assessed surgical decompression, which is a strategy with established efficacy.⁵⁸ In addition, the use of the Cochrane criteria of risk of bias may have resulted in a stringent evaluation of Phase I studies. While we acknowledge that the Cochrane criteria were primarily developed for application to randomized clinical trials, we felt it offered valuable insights.

Conclusions

Future research will benefit from addressing the methodological and conceptual concerns highlighted in the present study. The highest available evidence supports the use of combinatorial approaches containing rehabilitation techniques, and thus, novel therapeutic interventions should be tested in combinatorial approaches containing a well-defined rehabilitation component. Future research efforts that assess motor recovery should contain measures of viability of corticospinal fibers. We believe that this will lead to an improved understanding of the functional prognosis, and the role of the corticospinal and other pathways critical for motor recovery after SCI, and their response to therapeutic interventions.

Acknowledgements

The authors would like to thank Jordi Valles for his invaluable comments. Work on this study was supported by Fenexy Fundacion para la Curacion de Las Lesiones Medulares, Proyecto Volver a Caminar, Lazarus-Fenexy.

Author Disclosure Statement

Dr. Pascual-Leone serves on the scientific advisory boards for Nexstim, Neuronix, Starlab Neuroscience, Neuroelectronics, Axilum Robotics, Magstim Inc., and Neosync; and is listed as an inventor on several issued and pending patents on the real-time integration of transcranial magnetic stimulation (TMS) with electroencephalography (EEG) and magnetic resonance imaging (MRI). Dr. Guest serves on the scientific boards of Bioaxone and In Vivo Therapeutics. Mar Cortes' work is supported by grant NIH R21 HD069776. APL is supported in part by grants from the Sidney R. Baer Jr. Foundation, the National Institutes of Health (R01HD069776, R01NS073601, R21 MH099196, R21 NS082870, R21 NS085491, R21 HD07616), Harvard Catalyst | The Harvard Clinical and Translational Science Center (NCRR and the NCATS NIH, UL1 RR025758). The content is solely the responsibility of the authors and does not necessarily represent the official views of Harvard Catalyst, Harvard University and its affiliated academic health care centers, the National Institutes of Health or the Sidney R. Baer Jr. Foundation.

References

1. Birmingham A.
National spinal cord injury statistical center, facts and figures at a glance. [Prevalence of SCI (2013)]. March,2013.
2. Fawcett JW, Curt A, Steeves JD, et al. Guidelines for the conduct of clinical trials for spinal cord injury as developed by the ICCP panel: Spontaneous recovery after spinal cord injury and statistical power needed for therapeutic clinical trials. *Spinal Cord*. 2007;45(3):190-205.
3. Marino RJ, Barros T, Biering-Sorensen F, et al. International standards for neurological classification of spinal cord injury. *J Spinal Cord Med*. 2003;26 Suppl 1:S50-6.
4. Waring WP,3rd, Biering-Sorensen F, Burns S, et al. _ 2009 review and revisions of the international standards for the neurological classification of spinal cord injury. *J Spinal Cord Med*. 2010;33(4):346-352.
5. Bunge RP, Puckett WR, Hiester ED. Observations on the pathology of several types of human spinal cord injury, with emphasis on the astrocyte response to penetrating injuries. *Adv Neurol*. 1997;72:305-315.
6. Fitch MT, Silver J. CNS injury, glial scars, and inflammation: Inhibitory extracellular matrices and regeneration failure. *Exp Neurol*. 2008;209(2):294-301.
7. Steeves JD, Lammertse D, Curt A, et al. Guidelines for the conduct of clinical trials for spinal cord injury (SCI) as developed by the ICCP panel: Clinical trial outcome measures. *Spinal Cord*. 2007;45(3):206-221.

8. Bunge MB. Novel combination strategies to repair the injured mammalian spinal cord. *J Spinal Cord Med.* 2008;31(3):262-269.
9. McCreedy DA, Sakiyama-Elbert SE. Combination therapies in the CNS: Engineering the environment. *Neurosci Lett.* 2012;519(2):115-121.
10. Wenger N, Moraud EM, Raspopovic S, et al. Closed-loop neuromodulation of spinal sensorimotor circuits controls refined locomotion after complete spinal cord injury. *Sci Transl Med.* 2014;6(255):255ra133.
11. Gomes-Osman J, Cortes M, Pascual-Leone A. Assessment of different approaches for improving motor function after spinal cord injury in humans. University of York Centre for Reviews and Dissemination, PROSPERO International prospective register of systematic reviews. Web site. http://www.crd.york.ac.uk/PROSPERO/display_record.asp?ID=CRD42014009039#.U9uu6x7D9oy. Published 04/08/2014. Updated 2014. Accessed 08/01, 2014.
12. Liberati A, Altman DG, Tetzlaff J, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: Explanation and elaboration. *Ann Intern Med.* 2009;151(4):W65-94.
13. Higgins J, Green S. Cochrane handbook for systematic reviews of interventions version 5.1.0. The Cochrane Collaboration, 2011 Web site. <http://www.cochrane.org/handbook>. Updated 2011. Accessed 08/01, 2014.
14. Dai G, Liu X, Zhang Z, et al. Comparative analysis of curative effect of CT-guided stem cell transplantation and open surgical transplantation for sequelae of spinal cord injury. *J Transl Med.* 2013;11:315-5876-11-315.

15. Park HC, Shim YS, Ha Y, et al. Treatment of complete spinal cord injury patients by autologous bone marrow cell transplantation and administration of granulocyte-macrophage colony stimulating factor. *Tissue Eng.* 2005;11(5-6):913-922.
16. Zhou XH, Ning GZ, Feng SQ, et al. Transplantation of autologous activated schwann cells in the treatment of spinal cord injury: Six cases, more than five years of follow-up. *Cell Transplant.* 2012;21 Suppl 1:S39-47.
17. Knoller N, Auerbach G, Fulga V, et al. Clinical experience using incubated autologous macrophages as a treatment for complete spinal cord injury: Phase I study results. *J Neurosurg Spine.* 2005;3(3):173-181.
18. Lima C, Pratas-Vital J, Escada P, Hasse-Ferreira A, Capucho C, Peduzzi JD. Olfactory mucosa autografts in human spinal cord injury: A pilot clinical study. *J Spinal Cord Med.* 2006;29(3):191-203; discussion 204-6.
19. Chhabra HS, Lima C, Sachdeva S, et al. Autologous olfactory [corrected] mucosal transplant in chronic spinal cord injury: An indian pilot study. *Spinal Cord.* 2009;47(12):887-895.
20. Lima C, Escada P, Pratas-Vital J, et al. Olfactory mucosal autografts and rehabilitation for chronic traumatic spinal cord injury. *Neurorehabil Neural Repair.* 2010;24(1):10-22.
21. Mackay-Sim A, Feron F, Cochrane J, et al. Autologous olfactory ensheathing cell transplantation in human paraplegia: A 3-year clinical trial. *Brain.* 2008;131(Pt 9):2376-2386.
22. Kishk NA, Gabr H, Hamdy S, et al. Case control series of intrathecal autologous bone marrow mesenchymal stem cell therapy for chronic spinal cord injury. *Neurorehabil Neural Repair.* 2010;24(8):702-708.

23. Yazdani SO, Hafizi M, Zali AR, et al. Safety and possible outcome assessment of autologous schwann cell and bone marrow mesenchymal stromal cell co-transplantation for treatment of patients with chronic spinal cord injury. *Cytotherapy*. 2013;15(7):782-791.
24. Shapiro S, Borgens R, Pascuzzi R, et al. Oscillating field stimulation for complete spinal cord injury in humans: A phase 1 trial. *J Neurosurg Spine*. 2005;2(1):3-10.
25. Kumru H, Benito J, Murillo N, et al. Effects of high-frequency repetitive transcranial magnetic stimulation on motor and gait improvement in incomplete spinal cord injury patients. *Neurorehabil Neural Repair*. 2013;27(5):421-429.
26. Bunday KL, Perez MA. Motor recovery after spinal cord injury enhanced by strengthening corticospinal synaptic transmission. *Curr Biol*. 2012;22(24):2355-2361.
27. Beekhuizen KS, Field-Fote EC. Massed practice versus massed practice with stimulation: Effects on upper extremity function and cortical plasticity in individuals with incomplete cervical spinal cord injury. *Neurorehabil Neural Repair*. 2005;19(1):33-45.
28. Beekhuizen KS, Field-Fote EC. Sensory stimulation augments the effects of massed practice training in persons with tetraplegia. *Arch Phys Med Rehabil*. 2008;89(4):602-608.
29. Hoffman LR, Field-Fote EC. Functional and corticomotor changes in individuals with tetraplegia following unimanual or bimanual massed practice training with somatosensory stimulation: A pilot study. *J Neurol Phys Ther*. 2010;34(4):193-201.
30. Fehlings MG, Theodore N, Harrop J, et al. A phase I/IIa clinical trial of a recombinant rho protein antagonist in acute spinal cord injury. *J Neurotrauma*. 2011;28(5):787-796.
31. Chen HY, Lin JM, Chuang HY, Chiu WT. Raffinee in the treatment of spinal cord injury: An open-labeled clinical trial. *Ann N Y Acad Sci*. 2005;1042:396-402.

32. Grossman RG, Fehlings MG, Frankowski RF, et al. A prospective, multicenter, phase I matched-comparison group trial of safety, pharmacokinetics, and preliminary efficacy of riluzole in patients with traumatic spinal cord injury. *J Neurotrauma*. 2014;31(3):239-255.
33. Takahashi H, Yamazaki M, Okawa A, et al. Neuroprotective therapy using granulocyte colony-stimulating factor for acute spinal cord injury: A phase I/IIa clinical trial. *Eur Spine J*. 2012;21(12):2580-2587.
34. Inada T, Takahashi H, Yamazaki M, et al. Multicenter prospective nonrandomized controlled clinical trial to prove neurotherapeutic effects of granulocyte colony-stimulating factor for acute spinal cord injury: Analyses of follow-up cases after at least 1 year. *Spine (Phila Pa 1976)*. 2014;39(3):213-219.
35. Casha S, Zygun D, McGowan MD, Bains I, Yong VW, Hurlbert RJ. Results of a phase II placebo-controlled randomized trial of minocycline in acute spinal cord injury. *Brain*. 2012;135(Pt 4):1224-1236.
36. Maric O, Zorner B, Dietz V. Levodopa therapy in incomplete spinal cord injury. *J Neurotrauma*. 2008;25(11):1303-1307.
37. Alcobendas-Maestro M, Esclarin-Ruz A, Casado-Lopez RM, et al. Lokomat robotic-assisted versus overground training within 3 to 6 months of incomplete spinal cord lesion: Randomized controlled trial. *Neurorehabil Neural Repair*. 2012;26(9):1058-1063.
38. Dobkin B, Barbeau H, Deforge D, et al. The evolution of walking-related outcomes over the first 12 weeks of rehabilitation for incomplete traumatic spinal cord injury: The multicenter randomized spinal cord injury locomotor trial. *Neurorehabil Neural Repair*. 2007;21(1):25-35.
39. Wong AM, Leong CP, Su TY, Yu SW, Tsai WC, Chen CP. Clinical trial of acupuncture for patients with spinal cord injuries. *Am J Phys Med Rehabil*. 2003;82(1):21-27.

40. Li YL, Li LT, Yu M, Wang YZ, Ge HY, Song CQ. Beneficial effects of the herbal medicine di huang yin zi in patients with spinal cord injury: A randomized, placebo-controlled clinical study. *J Int Med Res.* 2012;40(5):1715-1724.
41. Wirz M, Zemon DH, Rupp R, et al. Effectiveness of automated locomotor training in patients with chronic incomplete spinal cord injury: A multicenter trial. *Arch Phys Med Rehabil.* 2005;86(4):672-680.
42. Fleerkotte BM, Koopman B, Buurke JH, van Asseldonk EH, van der Kooij H, Rietman JS. The effect of impedance-controlled robotic gait training on walking ability and quality in individuals with chronic incomplete spinal cord injury: An explorative study. *J Neuroeng Rehabil.* 2014;11:26-0003-11-26.
43. Field-Fote EC. Combined use of body weight support, functional electric stimulation, and treadmill training to improve walking ability in individuals with chronic incomplete spinal cord injury. *Arch Phys Med Rehabil.* 2001;82(6):818-824.
44. Segal JL, Pathak MS, Hernandez JP, Humber PL, Brunnemann SR, Charter RS. Safety and efficacy of 4-aminopyridine in humans with spinal cord injury: A long-term, controlled trial. *Pharmacotherapy.* 1999;19(6):713-723.
45. Buehner JJ, Forrest GF, Schmidt-Read M, White S, Tansey K, Basso DM. Relationship between ASIA examination and functional outcomes in the NeuroRecovery network locomotor training program. *Arch Phys Med Rehabil.* 2012;93(9):1530-1540.
46. van Hedel HJ, EMSCI Study Group. Gait speed in relation to categories of functional ambulation after spinal cord injury. *Neurorehabil Neural Repair.* 2009;23(4):343-350.
47. Sadowsky CL, Hammond ER, Strohl AB, et al. Lower extremity functional electrical stimulation cycling promotes physical and functional recovery in chronic spinal cord injury. *J Spinal Cord Med.* 2013;36(6):623-631.

48. Field-Fote EC, Lindley SD, Sherman AL. Locomotor training approaches for individuals with spinal cord injury: A preliminary report of walking-related outcomes. *J Neurol Phys Ther.* 2005;29(3):127-137.
49. Field-Fote EC, Roach KE. Influence of a locomotor training approach on walking speed and distance in people with chronic spinal cord injury: A randomized clinical trial. *Phys Ther.* 2011;91(1):48-60.
50. Jones ML, Evans N, Tefertiller C, et al. Activity-based therapy for recovery of walking in individuals with chronic spinal cord injury: Results from a randomized clinical trial. *Arch Phys Med Rehabil.* 2014;95(12):2239-46.e2.
51. Larson CA, Dension PM. Effectiveness of intense, activity-based physical therapy for individuals with spinal cord injury in promoting motor and sensory recovery: Is olfactory mucosa autograft a factor? *J Spinal Cord Med.* 2013;36(1):44-57.
52. Hayes HB, Jayaraman A, Herrmann M, Mitchell GS, Rymer WZ, Trumbower RD. Daily intermittent hypoxia enhances walking after chronic spinal cord injury: A randomized trial. *Neurology.* 2014;82(2):104-113.
53. Tanadini LG, Steeves JD, Hothorn T, et al. Identifying homogeneous subgroups in neurological disorders: Unbiased recursive partitioning in cervical complete spinal cord injury. *Neurorehabil Neural Repair.* 2014;28(6):507-515.
54. Mulcahey MJ, Gaughan J, Betz RR, Vogel LC. Rater agreement on the ISCSCI motor and sensory scores obtained before and after formal training in testing technique. *J Spinal Cord Med.* 2007;30 Suppl 1:S146-9.
55. Kobayashi M, Pascual-Leone A. Transcranial magnetic stimulation in neurology. *Lancet Neurol.* 2003;2(3):145-156.


56. Magistris MR, Rosler KM, Truffert A, Myers JP. Transcranial stimulation excites virtually all motor neurons supplying the target muscle. A demonstration and a method improving the study of motor evoked potentials. *Brain*. 1998;121 (Pt 3)(Pt 3):437-450.
57. Freund P, Curt A, Friston K, Thompson A. Tracking changes following spinal cord injury: Insights from neuroimaging. *Neuroscientist*. 2013;19(2):116-128.
58. Fehlings MG, Vaccaro A, Wilson JR, et al. Early versus delayed decompression for traumatic cervical spinal cord injury: Results of the surgical timing in acute spinal cord injury study (STASCIS). *PLoS One*. 2012;7(2):e32037.

Figure and Table legends



Figure 1. Flow chart displaying the search strategy.

Journal of Neurotrauma
A systematic review of experimental strategies aimed at improving motor function after acute and chronic spinal cord injury. (doi: 10.1089/neu.2014.3812)
This article has been peer-reviewed and accepted for publication, but has yet to undergo copyediting and proof correction. The final published version may differ from this proof.



Journal of Neurotrauma
A systematic review of experimental strategies aimed at improving motor function after acute and chronic spinal cord injury. (doi: 10.1089/neu.2014.3812)
This article has been peer-reviewed and accepted for publication, but has yet to undergo copyediting and proof correction. The final published version may differ from this proof.

This article has been peer-reviewed and accepted for publication, but has yet to undergo copyediting and proof correction. The final published version may differ from this proof.

Journal of Neurotrauma

A systematic review of experimental strategies aimed at improving motor function after acute and chronic spinal cord injury. (doi: 10.1089/neu.2014.3812)

	Random sequence generation (selection bias)	Allocation concealment (selection bias)	Blinding of participants and personnel (performance bias)	Blinding of outcome assessment (detection bias)	Incomplete outcome data (attrition bias)	Selective reporting (reporting bias)	Other bias
Alcobendas-Maestro 2012	+	+	+	+	+	+	-
Amr 2013	-	-	-	-	-	-	-
Beekhuizen 2005	+	-	-	+	-	-	-
Beekhuizen 2008	+	-	-	-	-	-	-
Buehner 2012	-	-	-	-	+	+	-
Bunday 2012	+	+	+	+	-	-	-
Casha 2012	+	+	+	+	+	+	-
Chen 2005	-	-	-	-	+	+	-
Chhabra 2009	-	-	-	-	+	+	-
Dai 2013	-	-	+	-	-	-	-
Dobkin 2007	+	+	-	-	+	+	-
Fehlings 2011	-	-	-	-	+	+	-
Field-Fote 2001	-	-	-	-	+	+	-
Field-Fote 2005	+	-	-	-	-	-	-
Field-Fote 2011	+	-	+	-	+	+	-
Fleerkotte 2014	-	-	-	-	+	+	-
Grossman 2014	-	-	-	-	+	+	-
Hayes 2014	+	+	+	+	+	+	-
Hoffman 2013	+	+	-	-	+	+	-
Inada 2014	-	-	-	-	+	+	-
Jones 2014	+	+	+	+	+	+	-
Kishk 2010	-	-	-	-	+	-	-
Knoller 2005a	-	-	-	-	-	-	-
Kumru 2013	+	-	+	-	-	-	-
Larson 2013	-	-	-	-	+	+	-
Li 2012	+	+	+	+	+	+	-
Lima 2006	-	-	-	-	-	-	-
Lima 2010	-	-	-	-	-	-	-
Mackay-Sim 2008	-	-	+	+	+	+	-
Maric 2008	+	-	-	-	+	+	-
Park 2005	-	-	-	-	-	-	-
Sadowsky 2013a	-	-	+	+	+	+	-
Segal 1999a	+	+	+	+	+	+	-
Shapiro 2005	-	-	-	-	+	+	-
Takahashi 2012	-	-	-	-	-	-	-
Wirz 2005	-	-	-	-	-	-	-
Wong 2003	-	-	-	-	-	-	-
Yazdani 2013	-	-	-	-	-	-	-
Zhou 2012	-	-	-	-	-	-	-

Figure 2a. Risk of bias graph: review authors' judgments about each risk of bias item (random sequence generation, allocation concealment, blinding of participants and personnel, blinding of outcome assessment, incomplete outcome data, selective reporting, other) presented as percentages across all included studies.

Figure 2b. Risk of bias summary: review authors' judgments about each risk of bias item for each included study.




Figure 3. Distribution of studies included in the review separated into acute/subacute SCI (light grey) and chronic SCI (dark grey) and included in the review according to the study phase (I-III, see methods).




Figure 4. Distribution of studies in acute/subacute and chronic SCI groups divided per phase (I-IV, see methods) for all categories (cell therapy, pharmacology, rehabilitation, electrical stimulation/neuroelectric device, combinatorial). SCI=spinal cord injury.

Table 1. Inclusion and exclusion criteria used in the present study. SCI=spinal cord injury.

Table 2. Criteria used to classify study phase (I, II, II, IV, from clinicaltrial.org).

Table 3. Approaches used in Acute/subacute SCI.

Table 4. Approaches used in chronic SCI.

Table 1.

	Inclusion Criteria	Exclusion Criteria
Population and condition	Adult human participants (19-70 years, sample size >5 participants) with a history of traumatic SCI: acute/subacute (defined as within minutes to 12 months post-injury) and/or chronic (after 12 months post-injury).	Studies exclusively in adolescents and children (age < 19 years old); Case studies/Case series (defined as having a sample size < 5 participants); Studies performed in animal models or experimental models of SCI; studies including individuals with non-traumatic SCI; Studies with participants who have other neurologic, cognitive or orthopaedic conditions associated with the SCI (metastatic cancer, etc).
Interventions	Cell therapies, pharmacology approaches, Electrical stimulation/neuroelectric devices, rehabilitation or a combination therapies including any of the above strategies.	Studies that: were not designed to assess the effects of an intervention (observational studies, studies carried out to assess an outcome measure); did not include a performance-based measure of motor function; assessed gangliosides and methylprednisolone, surgical decompression of the spinal cord, or were not available in full-text.
Comparisons of interest	Intervention versus active or inactive control; Pre-intervention/Post-intervention (for studies that did not include a control group)	None
Study design	Studies with an active control group (comparison group) were preferred, but studies with inactive controls (placebo or wait-list control), and safety/feasibility studies were also included.	Observational studies; Studies carried out using retrospective analysis of clinical findings and studies with no original data (reviews)
Timing/Setting	Longitudinal studies that occur in general and clinical settings	None

Table 1. Inclusion and exclusion criteria used in the present study. SCI=spinal cord injury.

Table 2.

Study Phase	Description
I	Study carried out to assess a new approach in a small sample for the first time to evaluate its safety, determine a safe dosage range, and identify side effects
II	Approach is given to a larger sample to see if it is effective, further evaluate safety and determine optimal dose
III	Approach is to a large sample to confirm effectiveness, monitor side effects, make comparisons to commonly used treatments, and collect information that will allow the approach to be used safely
IV	Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use

Table 2. Criteria used to classify study phase (I, II, II, IV, from clinicaltrial.org).

Table 3.

Study	Study Phase	Approach	Classification	Mechanism	Outcome Measure/ Effect (Clinical Neurological and/or motor performance)	Comparison/ Control	Direction of results	Follow-up	CS integrity	CS Connectivity
Whilings et al, 2011	Phase I	Cethrin	Pharmacology	↓ excitotoxicity	AIS scores	N/A	N/A	12 months	MRI	Absent
Chen et al, 2005	Phase I	Raffinee	Pharmacology	↓ excitotoxicity	AIS scores	N/A	N/A	2-3 weeks	Absent	Absent
Shapiro et al, 2005	Phase I	Implanted oscillating electric field	Electrical stimulation/ neuroelectric device	Neural guidance	AIS scores	N/A	N/A	6 months, 12 months	MRI- Excluded complete injuries	Absent
Park et al, 2005	Phase I	Bone-marrow derived mesenchymal stromal cells	Cell Therapy	Neural regeneration	AIS scores	N/A	N/A	6-18 months	MRI- Excluded complete injuries	Absent
Zhou et al, 2012	Phase I	Autologous activated Schwann cells	Cell Therapy	Neural regeneration	AIS scores, FIM	N/A	N/A	15-18 weeks, 5-8 years	MRI	MEPs (post-test)
Knoller et al, 2005	Phase I	Autologous macrophages	Cell Therapy	Neural regeneration	AIS scores	N/A	N/A	4-12 months	MRI	MEPs
Grossman et al, 2014	Phase II	Riluzole	Pharmacology	↓ excitotoxicity	AIS motor scores,* SCIM	Database control	*= ↑ Riluzole	42 days, 3 months, 6 months*	Absent	Absent
Kawahashi et al, 2012	Phase II	G-CSF	Pharmacology	↓ excitotoxicity	AIS motor scores†	Database control	† = ↑ (G-CSF)	3 months	Absent	Absent
Shah et al, 2012	Phase III	Minocycline	Pharmacology	↓ excitotoxicity	AIS scores, FIM, and SCIM	Placebo	No differences	3, 6 and 12 months	Absent	Absent

Inada et al, 2014	Phase II	G-CSF	Pharmacology	↓ excitotoxicity	AIS motor scores*	Control (no intervention)	*= ↑ (G-CSF)	1 year	Absent	Absent
Sumru et al, 2013	Phase III	High-frequency rTMS	Combination of Electrical stimulation/ neuroelectric device +Rehabilitation	Plasticity	Gait speed† and LEMS (AIS)†	Sham-rTMS +Rehabilitation	† = ↑ rTMS+Rehab	5 weeks	Absent	MEPs
Alcobenda Maestro et al, 2012	Phase III	Locomotor training (overground versus robotic orthosis)	Rehabilitation	Plasticity	FIM,† WISCI,† walking distance† and LEMS (AIS)†, walking speed	Overground locomotor training	† = ↑ robotic orthosis	8 weeks	Absent	Absent
Dobkin et al, 2007	Phase III	Locomotor training (overground versus treadmill)+Physical Therapy, Nursing	Combination of Rehabilitation +Nursing	Plasticity	Walking speed	Overground locomotor training	No differences	9 weeks	Absent	Absent
Wong et al, 2013	Phase III	Electrical and auricular acupuncture+ Rehabilitation	Combination of Rehabilitation techniques	Unknown	AIS scores, Functional Independence Measure†	Rehabilitation in isolation	† = ↑Rehab+ Acupuncture	12 months	Absent	Absent
Shi et al, 2012	Phase III	DHYZ	Pharmacology	Unknown	AIS scores*	Placebo	*= ↑ DHYZ group	12 weeks	Absent	Absent
Maric et al, 2009	Phase III	L-Dopa	Pharmacology	Plasticity	AIS scores, FIM, WISCI	Placebo	No differences	12 weeks	Absent	Absent
<p>Note: * Refers to between-group differences and †refers to pre-post differences. Phase I studies do not include a control/comparison group, and do not assess effectiveness (direction of results), therefore these items have been noted as applicable (N/A). (MRI=magnetic resonance imaging; MEP=motor evoked potentials; G-CSF= Granulocyte colony-stimulating factor; AIS= American Spinal Cord Injury Impairment Scale; FIM= Functional Independence Measure; SCIM=Spinal Cord Independence Measure; WISCI=walking index for spinal cord injury; rTMS=replicative transcranial magnetic stimulation; LEMS=lower extremity motor scores obtained from AIS assessment; DHYZ= Di Huang Yin Zi, a traditional Chinese medicine).</p>										

Table 3. Approaches used in Acute/subacute SCI.

Table 4.

Study	Study Phase	Approach	Classification	Mechanism	Outcome Measure (Clinical Neurological and/or motor performance)	Comparison/Control	Direction of results	Follow-up	SC integrity	SC Connectivity
Lima et al, 2006	Phase I	Olfactory mucosal autografts	Cell Therapy	Neural regeneration	AIS scores	N/A	N/A	6, 12 and 18 months	MRI	Absent
Chhabra et al, 2009	Phase I	Olfactory ensheathing cells	Cell Therapy	Neural regeneration	AIS scores, WISCI, SCIM	N/A	N/A	6, 12 and 18 months	MRI (only included lesions 2-3cm)	MEPs
Wirz et al, 2005	Phase I	Locomotor training (gait-driven orthosis)	Rehabilitation	Plasticity	LEMS, 6-min walk test, 10 m walk, timed up and go, WISCI-II	N/A	N/A	Post-intervention (8 weeks)	Absent	Absent
Yazdani et al, 2013	Phase I	Bone-marrow mesenchymal stromal cells, Schwann cells and rehabilitation	Combination of Cell Therapy + Rehabilitation	Neural regeneration+ Plasticity	AIS scores	N/A	N/A	24 months	MRI- Excluded stenosis and tethering of the spinal cord	Absent
Field-Fote et al, 2001	Phase I	Body-weight supported treadmill training + electrical stimulation	Combination of Rehabilitation+ Electrical stimulation/ neuroelectric device	Plasticity	2 min walk (speed), LEMS	N/A	N/A	Post-intervention (12 weeks)	Absent	Absent
Fleerkote et al, 2014	Phase I	Body-weight supported treadmill training (AAN-RO)	Combination of Rehabilitation+ Electrical stimulation /neuroelectric device	Plasticity	10 m walk† (distance), WISCI, TUG†, 6 minute walk†, LEMS†	N/A	N/A	8 weeks	Absent	Absent

Segal et al, 1999	Phase II	4-aminopyridine (low, high dose)	Pharmacology	Plasticity	AIS motor scores†	Comparison (unblinded high dose)	†=groups collapsed	3 months	Absent	Absent
Buehner et al, 2012	Phase II	Manual facilitated body weight-supported step training on a treadmill + community reintegration	Combination of rehabilitation + other	Plasticity	LEMS,† UEMS,† 6-minute walk (speed and distance),† and 10-meter walk (speed)†	N/A	† = pre-post difference	mean of 60.3±53.24 sessions (approximately 5 months)	Absent	Absent
Bunday et al, 2012	Phase II	Transcranial magnetic stimulation paired with electrical stimulation	Combination of Electrical stimulation/ neuroelectric device	Plasticity	NHPT*	Comparison group	* = † TMS+stim	post-test (single session)	Absent	MEPs
Beekhuizen et al, 2005	Phase III	Upper extremity task-specific training and submotor threshold electrical stimulation (TST+stim versus TST)	Combination of Electrical stimulation/ neuroelectric device + Rehabilitation	Plasticity	JTT,* WMFT,* pinch strength*	Comparison group (TST)	Between-group difference= * ↑ TST+stim	3 weeks	Absent	MEPs
Beekhuizen et al, 2008	Phase III	Upper extremity task-specific training and submotor threshold electrical stimulation (TST+stim, TST, stim and waitlist control)	Combination of Electrical stimulation/ neuroelectric device + Rehabilitation	Plasticity	JTT,* WMFT,* pinch strength*	Control group (waitlist)	Between-group difference= * ↑ TST+stim	3 weeks	Absent	MEPs
Hoffman et al, 2010	Phase III	Upper extremity task-specific training (unimanual, bimanual) and electrical stimulation (submotor threshold and FES), and waitlist control	Combination of Electrical stimulation/ neuroelectric device + Rehabilitation	Plasticity	JTT,†	Rehabilitation in isolation	† = pre-post difference (groups collapsed)	3 weeks	Absent	MEPs
Sadowsky et al, 2013	Phase III	FES cycling	Combination of Rehabilitation+ Electrical stimulation /neuroelectric device	Plasticity	AIS scores†, AIS motor† scores, FIM†	Control (no intervention)	†=FES	Mean of 29.1 months	Absent	Absent

Field-Fote et al, 2005	Phase III	Body-weight supported treadmill training + electrical stimulation (TM, OG, TS and LR)	Combination of Rehabilitation+ Electrical stimulation /neuroelectric device	Plasticity	6 minute walk, † 2 minute walk †	Comparison group	† = pre-post difference (groups collapsed)	12 weeks	Absent	Absent
Field-Fote et al, 2011	Phase III	Body-weight supported treadmill training + electrical stimulation (TM, OG, TS and LR)	Combination of Rehabilitation+ Electrical stimulation /neuroelectric device	Plasticity	10 m walk (distance) *	Comparison group	Between-group difference= * † OG	12 weeks	Absent	Absent
Jones et al, 2014	Phase III	ABT	Rehabilitation	Plasticity	AIS motor score, * LEMS, * 10 meter walk, * 6 minute walk, * TUG, SCIM-III, SCI-FAI, * RNL index,	Waitlist control	*=† ABT	24 weeks	Absent	Absent
Dai et al, 2013	Phase III	Mesenchymal stem cells (OS, CT, control)	Cell Therapy	Neural Regeneration	AIS scores† ¹ , MEPs, AIS motor scores† ²	Control (no intervention)	† ¹ =OS, CT † ² =CT	6 months	MRI (guided injection site)	MEP
Mackay-Sim et al, 2008	Phase III	Olfactory ensheathing cell transplant	Cell Therapy	Neural regeneration	AIS scores, FIM, IADL, COVS	Control group	No differences	3 years	MRI	MEPs
Lima et al, 2010	Phase III	Olfactory mucosal autografts + Locomotor training	Combination of Cell Therapy + Rehabilitation	Plasticity + Neural regeneration	LEMS, † FIM † and WISCI †	Comparison group	† = pre-post difference (groups collapsed)	Mean of 27.7 months	MRI (only included lesions 3-4cm)	Absent
Larson et al, 2013	Phase III	Locomotor training (olfactory mucosal transplant and control)	Combination of Cell Therapy + Rehabilitation	Plasticity + Neural regeneration	AIS scores †	Control group	† = pre-post difference (groups collapsed)	60 days	Absent	Absent
Kishk et al, 2010	Phase III	Bone-marrow + rehabilitation	Combination of Cell Therapy +	Plasticity + Neural	AIS scores	Control group	No differences	1 year	MRI	Absent

		Rehabilitation	regeneration							
Hayes et al, 2014	Phase III	Daih + LT (Daih, Sham-Daih, Daih+LT, Sham-Daih+LT)	Combination of Pharmacology+ Rehabilitation	Plasticity	10 m walk (time) †, * 6 minute walk †, † ¹ , † ² , * ¹	Sham-Daih, Sham-Daih+LT (Crossover design)	†=Daih *=† Daih † ¹ =Sham-Daih † ² =Daih+LT * ¹ =† Daih+LT	Day1, Day 5, 1 week and 2 weeks	Absent	Absent
<p>Note: * Refers to between-group differences and † refers to pre-post differences (MRI=magnetic resonance imaging; MEP= motor evoked potentials; AIS= American Spinal Cord Injury Impairment Scale; UEMS=upper extremity motor scores obtained from AIS assessment; LEMS=lower extremity motor scores obtained from AIS assessment; AAN-RO=assist-as-needed robotic orthosis; NHPT=nine-hole peg test; WMFT=wolf motor function test; TST=task-specific training; stim=electrical stimulation; FES=functional electrical stimulation; TM=treadmill training with manual assistance; OG=overground training; TS=treadmill training with electrical stimulation; LR=locomat robotic orthosis training; FIM= Functional Independence Measure; WISCI=walking index for spinal cord injury; SCIM=Spinal Cord Independence Measure; ABT=activity-based therapy; TUG=timed up and go; SCI-FAI=Spinal Cord Injury Functional Ambulation Index; RNL Index=Reintegration to Normal Living; TUG=timed up and go; OS=open surgery; CT=computed tomography-guided; IADL=Lawton's instrumental activities of daily living; COVS=Clinical outcomes variable scale; Daily acute intermittent hypoxia (Daih); locomotor training (LT).</p>										

Table 4. Approaches used in chronic SCI.

A systematic review of experimental strategies aimed at improving motor function after acute and chronic spinal cord injury. (doi: 10.1089/neu.2014.3812)
This article has been peer-reviewed and accepted for publication, but has yet to undergo copyediting and proof correction. The final published version may differ from this proof.